Stewart Albert, MD
Endocrinology, Diabetes & Metabolism · St Louis, MONPI 1417967969
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $24,075 of the $24,736 with a category attached, or 97.3%. Vertex accounts for 94.1% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $16,529, more than ten times the $135 reported in 2019.
Across 43 payments — averaging $575.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vertex$23K
- Astrazeneca UK Limited$800
- Amgen$254
- Novo Nordisk$172
- Abbott$80
- Dexcom, Inc.$74
- plus $82 from 4 others
Across 8 payments — averaging $2503.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$20K
What the payments were for
- Consulting fees$24,07597%
- Food & beverage$6613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vertex | 19 | $23,275 |
| Astrazeneca UK Limited | 1 | $800 |
| Amgen | 2 | $254 |
| Novo Nordisk | 8 | $172 |
| Abbott | 4 | $80 |
| Dexcom, Inc. | 4 | $74 |
| Ascendis Pharma Endocrinology Inc | 2 | $32 |
| Medtronic | 1 | $24 |
| Lilly USA, LLC | 1 | $13 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,736 in reported general payments places this provider in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 253 | $413,477 |
| OzempicSemaglutide | 149 | $204,587 |
| JardianceEmpagliflozin | 133 | $162,601 |
| MounjaroTirzepatide | 30 | $41,481 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $31,730 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 177 | $31,340 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $29,890 |
| RybelsusSemaglutide | 12 | $23,112 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $21,976 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $20,555 |
| FarxigaDapagliflozin Propanediol | 20 | $20,117 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 42 | $14,671 |
| JanuviaSitagliptin Phosphate | 11 | $9,785 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $8,895 |
| Humalog Kwikpen U-100Insulin Lispro | 23 | $4,674 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $13 | $454,958283 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $172 | $229,299172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in St Louis
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
- James BonucchiSpringfield$128K
- Christopher CaseJefferson City$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.